| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 15 analysts have evaluated Inspire Medical Systems (NYSE:INSP), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 8 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 6 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Inspire Medical Systems, revealing an average target of $144.4, a high estimate of $230.00, and a low estimate of $89.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 28.03%.
The standing of Inspire Medical Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Danielle Antalffy | UBS | Lowers | Neutral | $89.00 | $230.00 |
| Daniel Markowitz | Evercore ISI Group | Announces | Outperform | $150.00 | - |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $97.00 | $116.00 |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $116.00 | $149.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $125.00 | $190.00 |
| Frank Takkinen | Lake Street | Lowers | Buy | $150.00 | $270.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $101.00 | $174.00 |
| Danielle Antalffy | UBS | Lowers | Buy | $230.00 | $270.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $180.00 | $215.00 |
| Jonathan Block | Stifel | Lowers | Hold | $140.00 | $175.00 |
| Adam Maeder | Piper Sandler | Lowers | Overweight | $150.00 | $233.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $110.00 | $195.00 |
| Brett Fishbin | Keybanc | Lowers | Overweight | $197.00 | $216.00 |
| Kallum Titchmarsh | Morgan Stanley | Lowers | Overweight | $182.00 | $200.00 |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $149.00 | $176.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Inspire Medical Systems showcased positive performance, achieving a revenue growth rate of 10.82% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.65%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Inspire Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of -0.55%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Inspire Medical Systems's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Inspire Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INSP
